[1] 余晨,高威,王智茹,等.胆道闭锁患儿Kasai手术后血清肝纤维化指标对预后的评估价值[J].中华肝胆外科杂志,2024,30(4):265-270.DOI:10.3760/cma.j.cn113884-20230729- 00014.
[2] 韩一江,季浩森,胡书奇,等.MMP-7、APRI与胆道闭锁肝纤维化的相关性分析[J].中华小儿外科杂志,2023,44(10):882-889.DOI:10.3760/cma.j.cn421158-20230602-00269.
[3] 徐晓丹,王雪婷,刘邵文,等.HDAC2的表达水平评分与胆道闭锁肝纤维化进展及预后的关系[J].中华小儿外科杂志,2023,44(10):874-881.DOI:10.3760/cma.j.cn421158- 20230601-00265.
[4] Zhang D, Zhang Y, Sun B. The molecular mechanisms of liver fibrosis and its potential therapy in application[J]. Int J Mol Sci, 2022, 23(20):12572. DOI: 10.3390/ijms232012572.
[5] 华群,周昕,丁泽全,等.Kasai手术前特异性超声征象评估胆道闭锁肝纤维化的价值[J].中华小儿外科杂志,2023,44(10):904-909.DOI:10.3760/cma.j.cn421158- 20230601-00264.
[6] Zhang L, Zhao C, Dai W, et al. Disruption of cholangiocyte-B cell crosstalk by blocking the CXCL12-CXCR4 axis alleviates liver fibrosis[J]. Cell Mol Life Sci, 2023, 80(12):379. DOI: 10.1007/s00018-023-05032-y.
[7] Lv Y, Li Y, Han X, et al. Expression of CXCL12-CXCR4/CXCR7 chemokines in splenic fibrosis of cirrhotic spleen and its therapeutic significance[J]. Arch Med Sci, 2023, 19(5):1569-1575. DOI: 10.5114/aoms/170910.
[8] 苏悦,宋虹霏,王鑫,等.黄芪甲苷经CXCL12/CXCR4信号轴及TXNIP/NLRP3炎性体路径抗肝纤维化的机制研究[J].中草药,2023,54(8):2453-2461.DOI:10.7501/j.issn.0253- 2670.2023.08.012.
[9] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.肝纤维化诊断及治疗共识(2019年)[J].中华肝脏病杂志,2019,27(9):657-667.DOI:10.3760/cma.j.issn.1007-3418.2019.09.001.
[10] 吴凤,唐维兵.胆道闭锁诊断新进展[J].中华实用儿科临床杂志,2017,32(23):1826-1828.DOI:10.3760/cma.j.issn.2095-428X.2017.23.020.
[11] 梁鉴坤,王晓蕾,萧云楠,等.胆道闭锁肝脏CX3CR1+T淋巴细胞的比例与肝纤维化及预后的相关性研究[J].中华小儿外科杂志,2023,44(10):890-896.DOI:10.3760/cma.j.cn421158-20230604-00274.
[12] 孙琦娴,穆敏,陶欣荣.CXC趋化因子配体12及其受体信号轴调控肺纤维化的研究进展[J].中华劳动卫生职业病杂志,2022,40(3):235-240.DOI:10.3760/cma.j.cn121094- 20210413-00196.
[13] 霍飞,侯佳璐,朱昱蒙,等.铁死亡诱导剂咪唑酮埃拉斯汀(IKE)通过抑制IL-6、CCL5及CXCL9分泌缓解CIA小鼠的肺纤维化[J].细胞与分子免疫学杂志,2024,40(2):114-120.DOI:10.13423/j.cnki.cjcmi.009673.
[14] 吴佳,范强,赵涤非,等.趋化因子配体12、趋化因子受体4、趋化因子受体7在食管癌中的的表达及意义[J].中华实验外科杂志,2023,40(12):2610-2613.DOI:10.3760/cma.j.cn421213-20230317-00149.
[15] 杨仁杰,张聪,陈灵芝,等.纤维连接蛋白1经PI3K/Akt途径调控肝星状细胞活化影响胆道闭锁肝纤维化[J].中华小儿外科杂志,2023,44(2):114-124.DOI:10.3760/cma.j.cn421158-20211116-00563.
[16] Zhang N, Ma Q, You Y, et al. CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction[J]. Int J Biol Sci, 2022, 18(3):1271-1287. DOI: 10.7150/ijbs.65802.
[17] Ullah A, Chen G, Yibang Z, et al. A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis[J]. Biomater Sci, 2022, 10(10):2650-2664. DOI: 10.1039/d2bm00242f. PMID: 35420075.
[18] 叶泽华,夏煜琦,李柏均,等.CXCR4在草酸钙晶体致肾损伤及纤维化中的作用和机制[J].中华泌尿外科杂志,2022,43(4):285-290.DOI:10.3760/cma.j.cn112330-20211018- 00552.
[19] Ahmedy OA, Kamel MW, Abouelfadl DM, et al. Berberine attenuates epithelial mesenchymal transition in bleomycin-induced pulmonary fibrosis in mice via activating A2aR and mitigating the SDF-1/CXCR4 signaling[J]. Life Sci, 2023, 322:121665. DOI: 10.1016/j.lfs.2023. 121665.
[20] 王雪婷,徐晓丹,李梦迪,等.CCL25/CCR9在胆道闭锁肝纤维化中的表达及临床意义[J].中华小儿外科杂志,2023,44(10):897-903.DOI:10.3760/cma.j.cn421158- 20230601-00266.
|